MAP3K7
MAP3K7 (mitogen-activated protein kinase kinase kinase 7, also known as TAK1 and MEKK7) is a serine/threonine kinase and an essential component of the MAP kinase signal transduction pathway. It relays signals from cytokines, TGF-beta family members and toll-like receptors to the JNK, p38 MAPK and NF-kappa-B pathways. Browse Assay Genie's current range of MAP3K7 research reagents below, or read on for the biology behind the target.
MAP3K7 plays an important role in the cascades of cellular responses evoked by changes in the environment. It mediates signal transduction downstream of TRAF6, interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors such as BMP2 and BMP4, toll-like receptors, the tumour necrosis factor receptor CD40 and the B-cell receptor. Once activated, it acts upstream of the MKK/JNK and p38 MAPK cascades by phosphorylating and activating MAP kinase kinases including MAP2K1, MAP2K3, MAP2K6 and MAP2K7. These in turn activate p38 MAPKs and c-jun N-terminal kinases (JNKs), and both pathways control the transcription factor AP-1.
Independently of MAP2Ks and p38 MAPKs, MAP3K7 is a key activator of NF-kappa-B. It is recruited to polyubiquitin chains of RIPK2 and IKBKG/NEMO through TAB2 and TAB3, then phosphorylates and activates IKBKB, a component of the I-kappa-B-kinase (IKK) complex. In response to IL-1, it forms a kinase complex with TRAF6, TAB1 and TAB2 that is required for NF-kappa-B activation. In osmotic stress signalling it is a major activator of JNK1 (MAPK8) but not of NF-kappa-B. It also phosphorylates RIPK1 at Ser-321, which promotes interaction with RIPK3 and necroptosis while restraining RIPK1 kinase activity and FADD-mediated apoptosis, and phosphorylates STING1 after cGAMP activation. It promotes TRIM5 capsid-specific restriction activity.
The MAP3K7 gene encodes a member of the protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase kinase subfamily. HGNC places it in the mitogen-activated protein kinase kinase kinases and the mixed lineage kinase family. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. Mouse and rat orthologs are both named Map3k7.
MAP3K7 transduces toll-like receptor, IL-1 and TRAF6 signals, making it central to studies of how cells activate NF-kappa-B and AP-1 responses.
The kinase mediates signalling induced by TGF-beta and BMP, linking these factors to transcription regulation and apoptosis.
MAP3K7 phosphorylates RIPK1 at Ser-321, influencing RIPK3 interaction, necroptosis and FADD-dependent apoptosis.
MAP3K7 drives JNK activation in osmotic stress and phosphorylates STING1 after cGAMP activation, supporting work on environmental and antiviral responses.
MAP3K7 is a serine/threonine kinase that sits upstream of the JNK and p38 MAPK cascades through phosphorylation of MAP2Ks such as MAP2K3, MAP2K6 and MAP2K7. It also activates NF-kappa-B by phosphorylating IKBKB in the IKK complex, and regulates RIPK1 and STING1.
MAP3K7 is also known as TAK1 and MEKK7, and its full name is mitogen-activated protein kinase kinase kinase 7. Its partners TAB1, TAB2 and TAB3 are also called MAP3K7P1, MAP3K7IP2 and MAP3K7IP3. Four alternatively spliced transcript variants encoding distinct isoforms have been reported.
Yes. Mouse and rat each have an ortholog named Map3k7, so the gene can be studied in common rodent models. Reactivity differs between reagents, so check the datasheet of any product for its validated reactivity.
Downstream MAP kinase kinases, other MAP3K family members and NF-kappa-B pathway targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O43318; product specifications from Assay Genie datasheets.